Company Overview

Harrow, Inc. is a U.S.-based ophthalmic pharmaceutical company focused on the development, production, and commercialization of prescription eye-care therapies. The company operates primarily within the ophthalmology and specialty pharmaceutical industries, with a business model centered on branded ophthalmic medications, compounded pharmaceutical products, and ophthalmic surgical solutions. Harrow’s core revenue drivers include prescription ophthalmic pharmaceuticals used in cataract surgery, dry eye disease, glaucoma, retinal disease management, and other ocular conditions affecting both surgical and chronic-care patient populations.

The company evolved from a compounding-focused pharmaceutical platform into a broader ophthalmic healthcare enterprise through acquisitions, licensing arrangements, and commercialization partnerships. Harrow has strategically concentrated its operations on ophthalmology, positioning itself as a specialized provider serving ophthalmologists, ambulatory surgery centers, retina specialists, and optometrists across the United States. Its differentiation has been tied to its focused ophthalmic portfolio, physician relationships, and efforts to improve access to branded and compounded ophthalmic therapies.

Business Operations

Harrow generates revenue primarily through sales of branded ophthalmic pharmaceuticals and compounded ophthalmic formulations. The company’s operations include commercial pharmaceutical distribution, ophthalmic drug manufacturing relationships, and specialty pharmacy-related activities. Harrow has historically operated through and alongside entities such as ImprimisRx, which provides compounded ophthalmic medications, and has expanded through ownership interests and acquisitions involving ophthalmic pharmaceutical assets. The company’s commercial focus includes therapies associated with cataract surgery, inflammation control, pupil dilation, dry eye treatment, and retinal care.

The company operates principally in the United States, with commercial infrastructure focused on domestic ophthalmic markets. Harrow controls and markets several ophthalmic brands and product rights obtained through acquisitions and licensing transactions. The company has also maintained relationships with external manufacturers, pharmaceutical partners, and specialty distribution channels to support commercialization and physician access. Public disclosures indicate strategic involvement with ophthalmic-focused subsidiaries and affiliated businesses tied to prescription access, compounding, and branded eye-care products.

Strategic Position & Investments

Harrow’s strategic direction has emphasized becoming a vertically integrated ophthalmic pharmaceutical platform with a concentrated portfolio of ophthalmology-focused products and commercial assets. Growth initiatives have included acquiring FDA-approved ophthalmic brands, expanding prescription access channels, increasing physician engagement, and building a broader ophthalmic product pipeline. The company has pursued acquisitions and licensing agreements designed to strengthen its position in surgical ophthalmology and chronic ocular disease treatment markets.

Notable transactions and investments have included ophthalmic product acquisitions and ownership interests in eye-care related businesses. Harrow has publicly emphasized long-term growth through branded ophthalmic pharmaceuticals, retina-focused therapies, and expanded commercialization capabilities. The company has also participated in investments and strategic relationships involving ophthalmic biotechnology and pharmaceutical development. Its strategic positioning reflects a specialized approach focused almost exclusively on ophthalmology rather than diversified pharmaceutical operations.

Geographic Footprint

Harrow’s principal operations and commercial activities are concentrated in the United States, where it markets ophthalmic pharmaceutical products to physicians, surgery centers, and healthcare providers. The company is headquartered in Tennessee, and its operating footprint is tied primarily to the domestic ophthalmic healthcare market. Public filings and company disclosures indicate that the majority of revenue is generated from U.S. operations.

Although Harrow’s commercial emphasis is domestic, some product sourcing, manufacturing relationships, and intellectual property arrangements involve international counterparties and supply-chain participants. The company’s market influence is primarily tied to the North American ophthalmic sector rather than broad multinational pharmaceutical distribution. Data regarding significant direct international operating revenue remains limited in publicly available disclosures.

Leadership & Governance

Harrow’s leadership team has been closely associated with its ophthalmic specialization strategy and acquisition-driven expansion. The company was founded with a focus on compounded pharmaceuticals and later evolved into a broader ophthalmic pharmaceutical organization under executive leadership emphasizing targeted specialty healthcare markets. Corporate governance and strategic execution have focused on portfolio expansion, physician access, and ophthalmic commercialization capabilities.

Key executives and leadership figures include:

• Mark L. Baum – Chief Executive Officer
• Andrew R. Boll – Chief Financial Officer
• Lori R. Tierney – Chief Commercial Officer
• Matthew D. Williams – General Counsel and Corporate Secretary

Management has publicly articulated a strategy centered on building a leading ophthalmic pharmaceutical platform through disciplined acquisitions, commercialization expansion, and long-term specialization in eye-care therapeutics. Public company disclosures, including SEC filings, investor materials, and earnings communications, consistently identify ophthalmology as the company’s central strategic focus.